Canned tuna products sold at major stores nationwide are being recalled for a potential botulism risk.

The U.S. Food and Drug Administration (FDA) recently posted a notice that Tri-Union Seafoods is recalling select lots of canned tuna products sold under the Genova, Van Camp’s, H-E-B and Trader Joe’s brand names.

The recall is being made out of an abundance of caution following a notification from the company’s supplier that the “easy open” pull tab can lid on limited products encountered a manufacturing defect that may compromise the integrity of the product seal (especially over time).

This can cause it to leak, or worse — be contaminated with clostridium botulinum, a potentially fatal form of food poisoning.

Consumers are warned not to use the products, even if they do not look or smell spoiled, according to the recall notice. Those feeling unwell should seek immediate medical attention.

READ FDA POSTING

AAHPO member Dr. Tro Kalayjian is a board-certified physician in Internal Medicine and Obesity Medicine and Medical Director of Toward Health. He recently published a paper in Frontiers of Nutrition which presents research confirming the health benefits of lifestyle-based metabolic care. Key findings include:

• 15.5% average body weight loss (43 lbs at 12 months)
• 76% of patients still losing weight at one year
• $2,000 saved per patient in deprescription costs
• 2 fewer medications per patient

READ MORE

By Samuel Badalian, Chair of Department of Obstetrics and Gynecology, Bassett Healthcare Network

I’m thrilled to share a major milestone for hashtag#Urogynecology in hashtag#Armenia! Today, our five fellows officially received their licenses from the hashtag#Ministry of Health, allowing them to practice the newly established subspecialty of Urogynecology and Reconstructive Pelvic Surgery.

This achievement is the result of four years of dedication and hard work. Since launching in 2021, our Urogynecology fellowship has trained specialists who can now provide evidence-based care in Armenia. This program was organized and implemented by the International Urogynecological Association for Armenia and supported by the Foundation for Urogynecological Assistance (FIUGA).

Congratulations to our fellows and everyone who contributed to this success!

COMMENT ON POST

Photo Credit: MedicalNews Today

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the Food and Drug Administration (FDA) says. The nasal spray is offered under the trade name SPRAVATO®.

AAHPO member and psychiatrist Louis Najarian, MD, helps us to understand what this means: “There is much excitement about the benefit of ketamine for treatment-resistant depression. The improvement is much better when ketamine is injected intravenously under the supervision of an anesthesiologist and nurse. The infusion usually takes two hours and requires two to three treatments per week until there is improvement. This treatment continues while under the care of the patient’s psychiatrist, including continuation of whatever interpretant medication is prescribed. It is obvious the nasal spray is easier to apply daily at home with supervision by the prescribing doctor. The intra venous delivery remains more effective.”

Treatment-resistant depression is defined as major depressive disorder (MDD) that has shown an inadequate response to at least two oral antidepressants. MDD is one of the most common psychiatric disorders, with an estimated 21 million adults in the U.S. living with MDD. About one-third of adults will not respond to oral antidepressants alone, which has a significant negative impact on the quality of life of those affected. MDD has a high economic burden, with nearly half of it attributable to treatment-resistant depression (TRD).

Learn more about Spravato